These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 29412119)

  • 21. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence.
    Scheen AJ; Paquot N
    Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S4-S11. PubMed ID: 25554070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist.
    Bethel MA; McMurray JJV
    Circulation; 2018 Mar; 137(12):1218-1220. PubMed ID: 29555706
    [No Abstract]   [Full Text] [Related]  

  • 24. The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia.
    Loutradis C; Papadopoulou E; Angeloudi E; Karagiannis A; Sarafidis P
    Curr Med Chem; 2020; 27(39):6682-6702. PubMed ID: 31663470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular Outcomes With the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes and Chronic Kidney Disease: An Updated Meta-Analysis of Randomized Controlled Trials.
    Malik AH; Yandrapalli S; Goldberg M; Jain D; Frishman WH; Aronow WS
    Cardiol Rev; 2020; 28(3):116-124. PubMed ID: 31868769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events.
    Nelson AJ; Harrington JL; Kolkailah AA; Pagidipati NJ; McGuire DK
    Heart Fail Clin; 2022 Oct; 18(4):597-607. PubMed ID: 36216489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk Management.
    Katsiki N; Mikhailidis DP; Theodorakis MJ
    Curr Pharm Des; 2017; 23(10):1522-1532. PubMed ID: 28088910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The mechanisms and clinical potential: sodium-glucose cotransporter 2 (SGLT-2) inhibitors treating diabetic kidney disease].
    Wang YJ; Hao CM
    Sheng Li Xue Bao; 2018 Dec; 70(6):663-669. PubMed ID: 30560277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors for Cardiovascular Disease Prevention.
    Reid J; Rana K; Niman S; Sheikh-Ali M; Lewis T; Choksi RR; Goldfaden RF
    Am J Cardiovasc Drugs; 2020 Oct; 20(5):419-429. PubMed ID: 32043244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SGLT-2 inhibitors in Diabetic Kidney Disease: What Lies Behind their Renoprotective Properties?
    Georgianos PI; Divani M; Eleftheriadis T; Mertens PR; Liakopoulos V
    Curr Med Chem; 2019; 26(29):5564-5578. PubMed ID: 29792136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of Sodium-Glucose Cotransporter-2 Inhibition in the Treatment of Adults With Heart Failure.
    Sharma A; Ezekowitz JA
    Can J Diabetes; 2020 Feb; 44(1):103-110. PubMed ID: 31630988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse effects and safety of SGLT-2 inhibitors.
    Halimi S; Vergès B
    Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S28-34. PubMed ID: 25554069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel oral hypoglycemic agents SGLT-2 inhibitors: cardiovascular benefits and potential mechanisms.
    Li W; Yu K; Sun S
    Pharmazie; 2020 Jun; 75(6):224-229. PubMed ID: 32539914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebrovascular Complications of Diabetes: SGLT-2 Inhibitors as a Promising Future Therapeutics.
    Chavda V; Vashi R; Patel S
    Curr Drug Targets; 2021; 22(14):1629-1636. PubMed ID: 33081674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
    Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
    Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD.
    Ala M
    Endocrinology; 2021 Dec; 162(12):. PubMed ID: 34343274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Extraglycemic Effect of SGLT-2is on Mineral and Bone Metabolism and Bone Fracture.
    Dong B; Lv R; Wang J; Che L; Wang Z; Huai Z; Wang Y; Xu L
    Front Endocrinol (Lausanne); 2022; 13():918350. PubMed ID: 35872985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
    Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
    Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
    Vallon V; Thomson SC
    Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.